SCHEMBL1379909

SCHEMBL1379909

O=C(NCCCN1CCOCC1)c1ccc2c(c1)ncn2-c1cccc(OCCCOc2ccc(F)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
FGFR1 P11362 3/20 0.57
SRC P12931 3/20 0.57
USP2 O75604 1/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.54
HSD17B10 Q99714 1/20 0.54
DRD3 P35462 1/20 0.51
MAPK1 P28482 3/20 0.49
ALDH1A1 P00352 1/20 0.49
EPHX2 P34913 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1377307 0.94 MEN1 (0.65) HPGDKMT2AMEN1FGFR1SRC
SCHEMBL1380132 0.92 MEN1 (0.65) HPGDKMT2AMEN1FGFR1SRC
SCHEMBL1381939 0.92 KMT2A (0.54) HPGDKMT2AMEN1DRD3MAPK1
SCHEMBL1378868 0.90 MEN1 (0.59) HPGDKMT2AMEN1FGFR1SRC
SCHEMBL1378814 0.87 L3MBTL1 (0.58) HPGDKMT2AMEN1FGFR1SRC
SCHEMBL1381954 0.84 KMT2A (0.58) HPGDKMT2AMEN1FGFR1SRC
SCHEMBL1378425 0.83 KMT2A (0.58) HPGDKMT2AMEN1USP2TSHR
SCHEMBL1377663 0.82 HPGD (0.69) HPGDKMT2AMEN1MAPK1CYP1A2
SCHEMBL1378469 0.82 MAPK1 (0.49) HPGDKMT2AMEN1FGFR1SRC
SCHEMBL1379900 0.82 KMT2A (0.57) HPGDKMT2AMEN1FGFR1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4769720-B2 2011-09-07 JP claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US claimed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US claimed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP claimed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K HPGD 1154/4885KMT2A 518/4885MEN1 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.